Evidence map›Paper›PMID 42289038›Full record

ArticleDiscover oncology2026

NEMF inhibits the proliferation and migration of ovarian cancer cells by blocking the PI3K/mTOR pathway.

Qian Wang, Ying Zhu, Chuangzhen Chen, Jing Fan, Ruifang Zeng, Zike Yang, Shanshan Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qian Wang *Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510315, China.
Ying Zhu *Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510315, China.
Chuangzhen ChenDepartment of Obstetrics and Gynecology, Dongguan Binhaiwan Central Hospital, Southern Medical University, Dongguan, 523000, China.
Jing FanDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510315, China.
Ruifang ZengCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510315, China.
Zike YangDepartment of Oncology, Zhongshan Hospital of Xiamen University, chool of Medicine, Xiamen University, Xiamen, Fujian, China.
Shanshan SongCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510315, China. shanshan2007@foxmail.com.

Funding

Guangdong Provincial Medical Research Fund A2024755Guangdong Yiyang Health Charity Foundation JZ2024045
6 · The paper itself

Abstract

backgroundNuclear export mediator factor (NEMF) is considered to be a tumor suppressor in Drosophila. Based on the analysis of data from an online database, NEMF is downregulated in OV. However, the mechanism underlying its expression has not been reported thus far.

resultsIn this study, the immunohistochemistry results showed that the expression of NEMF may be related to patient age and tissue differentiation. In vitro experiments indicated that overexpression of NEMF may inhibit cell proliferation and migration by inhibiting the PI3K/mTOR signaling pathway, thereby blocking cell cycle progression and promoting apoptosis (P < 0.05). In vivo xenografts showed NEMF overexpression reduced tumor volume and proliferation markers (Ki-67, PCNA).

conclusionsWe speculate that NEMF is a potential tumor suppressor gene. Targeting NEMF may be an innovative therapeutic approach for OV.

Indexed as

Cell cycleNEMFOvarian cancerPI3K/mTOR signaling pathwayPrognosis

Identifiers

PMID42289038
PMCPMC13490334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.